OBJECTIVES: The aim of this study was to compare two regimens of chemotherapy in patients with breast cancer, including FAC (doxorubicin, cyclophosphamide, and 5-fluorouracil) and TAC (docetaxel, doxorubicin and cyclophosphamide); and analyze the toxicity of these treatments and observe patient's health-related quality of life. METHODS: Health-related quality of life was assessed for up to 4 months (from the beginning to the end of chemotherapy cycles), using European organization and cancer treatment quality of life questionnaire (EORTC) QLQ-C30. A group of 100 patients, with node-positive breast cancer were studied in order to compare the toxicity of adjuvant therapy TAC with FAC and the subsequent effects on the patient's quality of life. RESULTS: After a 4-month follow-up of patients, our findings showed that despite having the same mean score of QOL at the start of adjuvant chemotherapy, the QOL in TAC arm was decreased more as a result of the higher range of toxicity in TAC regimen. CONCLUSION: In spite of increase in disease-free patients who received TAC regimen and increase their survival rate, there is significant toxicity and decrease in QOL in TAC protocol compare to FAC protocol. Using prophylactic granulocyte colony stimulating factor (G-CSF) along with increased education aimed at improving patient's knowledge and also the provision of a supportive group involving psychiatrics and patients that have successfully experienced the same treatment may be helpful.
OBJECTIVES: The aim of this study was to compare two regimens of chemotherapy in patients with breast cancer, including FAC (doxorubicin, cyclophosphamide, and 5-fluorouracil) and TAC (docetaxel, doxorubicin and cyclophosphamide); and analyze the toxicity of these treatments and observe patient's health-related quality of life. METHODS: Health-related quality of life was assessed for up to 4 months (from the beginning to the end of chemotherapy cycles), using European organization and cancer treatment quality of life questionnaire (EORTC) QLQ-C30. A group of 100 patients, with node-positive breast cancer were studied in order to compare the toxicity of adjuvant therapy TAC with FAC and the subsequent effects on the patient's quality of life. RESULTS: After a 4-month follow-up of patients, our findings showed that despite having the same mean score of QOL at the start of adjuvant chemotherapy, the QOL in TAC arm was decreased more as a result of the higher range of toxicity in TAC regimen. CONCLUSION: In spite of increase in disease-freepatients who received TAC regimen and increase their survival rate, there is significant toxicity and decrease in QOL in TAC protocol compare to FAC protocol. Using prophylactic granulocyte colony stimulating factor (G-CSF) along with increased education aimed at improving patient's knowledge and also the provision of a supportive group involving psychiatrics and patients that have successfully experienced the same treatment may be helpful.
Authors: Achim Wöckel; L Schwentner; M Krockenberger; R Kreienberg; W Janni; M Wischnewsky; Kühn Thorsten; Flock Felix; Felberbaum Riccardo; M Blettner; S Singer Journal: Qual Life Res Date: 2017-04-06 Impact factor: 4.147
Authors: Ricardo Fernandes; Sasha Mazzarello; Brian Hutton; Risa Shorr; Habeeb Majeed; Mohammed Fk Ibrahim; Carmel Jacobs; Michael Ong; Mark Clemons Journal: Support Care Cancer Date: 2016-05-05 Impact factor: 3.603
Authors: Stefanie de Groot; Maaike P G Vreeswijk; Marij J P Welters; Gido Gravesteijn; Jan J W A Boei; Anouk Jochems; Daniel Houtsma; Hein Putter; Jacobus J M van der Hoeven; Johan W R Nortier; Hanno Pijl; Judith R Kroep Journal: BMC Cancer Date: 2015-10-05 Impact factor: 4.430
Authors: Camelia Rohani; Heidar-Ali Abedi; Ramesh Omranipour; Ann Langius-Eklöf Journal: Health Qual Life Outcomes Date: 2015-03-28 Impact factor: 3.186